Video

Dr. Molena on Determining Surgical Resection Eligibility in NSCLC

Daniela Molena, MD, discusses factors that determine if a patient with non–small cell lung cancer is eligible for surgical resection.

Daniela Molena, MD, director, Esophageal Surgery Program, Memorial Sloan Kettering Cancer Center, discusses factors that determine if a patient with non—small cell lung cancer (NSCLC) is eligible for surgical resection.

Early-stage lung cancer is curable with surgery, explains Molena. If a high-risk patient presents with a nodule on their CT scan, it should not be ignored because it could progress into later-stage disease and render the patient ineligible for surgical resection.

Other factors such as the patient’s functional status and ability to tolerate anesthesia also determine if surgery is an option, says Molena.

The majority of patients with NSCLC have some degree of lung damage caused by smoking, explains Molena. As such, determining how much of the lung can be resected is another important consideration. In some cases, compromise must be made to ensure that enough lung can be removed without jeopardizing the patient’s postoperative function, says Molena.

For example, lobectomy remains the standard surgery for this patient population, says Molena. However, if a patient has low borderline pulmonary function and small cancer, less of the lung may be taken.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Victor Moreno, MD, PhD
Tiago Biachi, MD, PhD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.